2-氧代-1-哌嗪乙酸 | 24860-46-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氧代-1-哌嗪乙酸
• 英文名称: 2-oxo-1-piperazineacetic acid
• 英文别名: Ethylendiamin-N,N'-diessigsaeurelactam；2-(2-oxopiperazino)acetic acid；carboxymethyl-2-oxopiperazine；(2-oxo-piperazin-1-yl)-acetic acid；2-(2-Oxopiperazin-4-ium-1-yl)acetate；2-(2-oxopiperazin-4-ium-1-yl)acetate
• CAS: 24860-46-6
• 化学式: C₆H₁₀N₂O₃
• mdl: MFCD09838956
• 分子量: 158.157
• InChiKey: VYKYEBFQKSINNA-UHFFFAOYSA-N

物化性质

• 沸点：
  421.1±40.0 °C(Predicted)
• 密度：
  1.293

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Oxo-1-piperazineacetic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Oxo-1-piperazineacetic acid
CAS number: 24860-46-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H10N2O3
Molecular weight: 158.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氧代-1-哌嗪乙酸 在 sodium carbonate 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors

  摘要：

  A series of novel transition state factor Xa inhibitors containing a variety, of lactam ring systems as central templates was synthesized in an expedient manner and allowed for a great deal of structural variability. Among them. the piperazinone-based inhibitors were found to be not only active against factor Xa but also selective over thrombin. Optimization of the P4 moiety yielded several potent compounds with IC50 below 1 nM against factor Xa. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01037-5
• 作为产物：
  描述：

  2-[2-氨基乙基(羧甲基)氨基]乙酸 在 盐酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 2-氧代-1-哌嗪乙酸
  参考文献：
  名称：

  Complexes possessing ortho ligating functionality

  摘要：

  揭示了一组具有正交配位功能的官能化胺螯合剂，与稀土类金属离子形成络合物。这些螯合剂具有一般公式##STR1##其中R.sup.'1、R.sup.'2、R.sup.'3、R.sup.'4、R.sup.'5和R.sup.'6、Z'和X均在规范中定义。此外，某些螯合剂-放射性核素络合物可以有效地用于制剂，用作治疗和/或诊断钙化肿瘤和/或缓解骨疼痛的剂。

  公开号：

  US05342604A1

文献信息

• [EN] TARGETING COMPOUNDS<br/>[FR] COMPOSÉS DE CIBLAGE
  申请人：ZAFGEN INC

  公开号：WO2019118612A1

  公开（公告）日：2019-06-20

  The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  该披露提供了至少部分针对肝脏、肠道和/或肾脏的化合物，以及它们在治疗肝脏、肠道和/或肾脏疾病中的用途，如非酒精性脂肪肝、酒精性脂肪肝、肝细胞癌、肝硬化和乙型肝炎；和/或慢性肾脏疾病、肾小球疾病，如IgA肾病、狼疮性肾炎或多囊肾病。这些化合物被认为对甲硫氨酰氨肽酶2具有活性。
• [EN] BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-LACTAMASE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2014151958A1

  公开（公告）日：2014-09-25

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了一些能够调节β-内酰胺酶活性的化合物和组合物。在某些实施例中，所述化合物能够抑制β-内酰胺酶。在特定实施例中，所述化合物在治疗细菌感染方面具有用处。
• Particulate construct comprising polyhydroxyalkanoate and method for producing it
  申请人：——

  公开号：US20030194443A1

  公开（公告）日：2003-10-16

  The invention provides a particulate construct such as microcapsules containing a drug, and serving a slow releasing preparation not associated with a practically unacceptable initial burst release but showing a practically acceptable zero-order release for a certain period and a producing method for such particulate construct, and a slow releasing preparation of a high drug content capable of stably incorporating the drug in the particulate construct such as microcapsules, and a producing method for such preparation. The invention also provides a particulate construct such as microcapsules utilizing a highly functional polymer compound and incorporating oil phase and/or water phase in solid phase, and a producing method therefor. Furthermore, the invention provides a particulate construct such as microcapsules having a hollow structure of a single polymer membrane as the outer shell and capable of containing many bubbles in the fine particles, and a producing method capable of preparing such construct with a high reproducibility. According to the invention, a particulate construct such as microcapsules is formed with polyhydroxyalkanoate of a specified structure and a drug for a desired purpose, an oil phase and/or a water phase, or a gaseous phase is included in such construct.

  本发明提供了一种微粒构造物，例如包含药物的微胶囊，用作缓释制剂，不会出现实际上不可接受的初始爆发释放，但在一定时间内显示实际上可接受的零级释放，并提供了这种微粒构造物的制备方法，以及能够稳定地将药物纳入微粒构造物中，例如微胶囊的高药物含量的缓释制剂，以及这种制备方法。本发明还提供了一种利用高功能聚合物化合物并将油相和/或水相纳入固相的微粒构造物，以及其制备方法。此外，本发明还提供了一种具有单一聚合物膜的空心结构的微粒构造物，能够在细小的颗粒中包含许多气泡，并提供了一种能够高度重复制备这种构造物的制备方法。根据本发明，可使用具有特定结构的聚羟基烷酸酯和药物制备微粒构造物，该构造物中包含油相和/或水相或气态相。
• Benzoxazepine compounds, their production and use
  申请人：Yukimasa Hidefumi

  公开号：US20070117787A1

  公开（公告）日：2007-05-24

  This invention provides new benzoxazepine compounds represented by the formula: [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R 1 stands for a lower alkyl group and W stands for a halogen atom] having activities of lowering cholesterol-level and lowering triglyceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.

  本发明提供了一种新的苯并噁唑化合物，其表示为以下式子：[其中R代表可选地取代羟基的低碳基，X代表可选地取代的氨基甲酰基或具有可去质子氢原子的可选地取代的杂环基，R1代表低碳基，W代表卤素原子]，具有降低胆固醇水平和降低甘油三酯水平的活性，适用于预防和治疗高脂血症。
• Pyridine compounds as inhibitors of dipeptidyl peptidase IV
  申请人：Oi Satoru

  公开号：US20070037807A1

  公开（公告）日：2007-02-15

  A compound represented by the formula wherein R 1 and R 2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R 3 is an optionally substituted aromatic group; R 4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.

  该化合物的化学式为其中R1和R2是相同或不同的可选择取代的烃基或可选择取代的羟基；R3是可选择取代的芳香基；R4是可选择取代的氨基；L是二价链烃基；Q是键或二价链烃基；X是氢原子、氰基、硝基、酰基、可选择取代的羟基、可选择取代的硫醇基、可选择取代的氨基或可选择取代的环状基；但当X是乙氧羰基时，Q是二价链烃基。该化合物具有肽酶抑制作用，可用作预防或治疗糖尿病等药物，具有优异的疗效、持续时间、特异性、低毒性等特点。